Literature DB >> 7697533

The immunosuppressive human placental ferritin subunit p43 is produced by activated CD4+ lymphocytes.

B Garty1, E Kaminsky, C Moroz.   

Abstract

Human placental ferritin is an immunosuppressive protein composed of a 43-kDa subunit (p43) and ferritin light chains. Its physiological action seems to be downregulation of the immune response of the mother against her embryo. Elevated levels of p43 in serum are associated with pregnancy, lymphomas, breast cancer, and AIDS. Although it is known that p43 is produced by activated T lymphocytes, the specific T-lymphocyte subset involved is unknown. p43 is measured by enzyme-linked immunosorbent assays with CM-H-9 monoclonal antibody specific for p43. We studied the de novo biosynthesis of p43 by isolated activated CD4+ and CD8+ T lymphocytes in a normal donor and in a patient with elevated levels of p43 in serum. The results indicated that p43 was synthesized by activated CD4+ lymphocytes from the normal donor (0.45% of the total de novo proteins) but that its biosynthesis by CD8+ lymphocytes was below the level of detection. The activated CD4+ lymphocytes from the patient with elevated levels of p43 in serum overproduced p43 (3.8% of the nascent proteins). Since it was shown that a subset of CD8+ lymphocytes has receptors for p43, the latter may be considered an immunoregulatory cytokine produced mainly by activated CD4+ lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7697533      PMCID: PMC170132          DOI: 10.1128/cdli.2.2.225-226.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  11 in total

1.  Expression of p43 in breast cancer tissue, correlation with prognostic parameters.

Authors:  H R Rosen; C Moroz; A Reiner; M Stierer; J Svec; M Reinerova; M Schemper; R Jakesz
Journal:  Cancer Lett       Date:  1992-10-30       Impact factor: 8.679

2.  T-cell mitogenesis stimulates the synthesis of a mRNA species coding for a 43-kDa peptide reactive with CM-H-9, a monoclonal antibody specific for placental isoferritin.

Authors:  C Moroz; N Shterman; B Kupfer; I Ginzburg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

3.  Placental isoferritin as a physiological downregulator of cellular immunoreactivity during pregnancy.

Authors:  L Sirota; B Kupfer; C Moroz
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

4.  New monoclonal antibody enzymoassay for the specific measurement of placental ferritin isotype in hematologic malignancies.

Authors:  C Moroz; H Bessler; Y Lurie; M Shaklai
Journal:  Exp Hematol       Date:  1987-03       Impact factor: 3.084

5.  Induction of lymphocyte transformation by sequential treatment with neuraminidase and galactose oxidase.

Authors:  A Novogrodsky; E Katchalski
Journal:  Proc Natl Acad Sci U S A       Date:  1973-06       Impact factor: 11.205

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Preparation and characterization of monoclonal antibodies specific to placenta ferritin.

Authors:  C Moroz; B Kupfer; S Twig; B Parhami-Seren
Journal:  Clin Chim Acta       Date:  1985-05-30       Impact factor: 3.786

8.  Inhibitory effects of isoferritins from tumour and non-tumour tissues on E-rosette formation.

Authors:  H W Hann; M W Stahlhut; L C Chung
Journal:  Lancet       Date:  1984-01-07       Impact factor: 79.321

9.  Placental ferritin in coeliac disease: relation to clinical stage, origin, and possible role in the pathogenesis of malignancy.

Authors:  G Dinari; I Zahavi; H Marcus; C Moroz
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

10.  Specific binding sites for H-ferritin on human lymphocytes: modulation during cellular proliferation and potential implication in cell growth control.

Authors:  S Fargion; A L Fracanzani; B Brando; P Arosio; S Levi; G Fiorelli
Journal:  Blood       Date:  1991-08-15       Impact factor: 22.113

View more
  1 in total

1.  Identification of women with early breast cancer by analysis of p43-positive lymphocytes.

Authors:  L Auerbach; M Hellan; M Stierer; A C Rosen; C Ausch; R Obwegeser; E Kubista; G Wolf; H R Rosen; S Panzer
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.